tetano
Editor, Senior Moderator
Neurol Sci
. 2020 Oct 21.
doi: 10.1007/s10072-020-04801-y. Online ahead of print.
Neurological manifestations of COVID-19: a systematic review and meta-analysis of proportions
T T Favas[SUP] 1 [/SUP], Priya Dev[SUP] 1 [/SUP], Rameshwar Nath Chaurasia[SUP] 1 [/SUP], Kamlesh Chakravarty[SUP] 2 [/SUP], Rahul Mishra[SUP] 3 [/SUP], Deepika Joshi[SUP] 1 [/SUP], Vijay Nath Mishra[SUP] 1 [/SUP], Anand Kumar[SUP] 1 [/SUP], Varun Kumar Singh[SUP] 1 [/SUP], Manoj Pandey[SUP] 4 [/SUP], Abhishek Pathak[SUP] 5 [/SUP]
Affiliations
Abstract
Background: Coronaviruses mainly affect the respiratory system; however, there are reports of SARS-CoV and MERS-CoV causing neurological manifestations. We aimed at discussing the various neurological manifestations of SARS-CoV-2 infection and to estimate the prevalence of each of them.
Methods: We searched the following electronic databases; PubMed, MEDLINE, Scopus, EMBASE, Google Scholar, EBSCO, Web of Science, Cochrane Library, WHO database, and ClinicalTrials.gov . Relevant MeSH terms for COVID-19 and neurological manifestations were used. Randomized controlled trials, non-randomized controlled trials, case-control studies, cohort studies, cross-sectional studies, case series, and case reports were included in the study. To estimate the overall proportion of each neurological manifestations, the study employed meta-analysis of proportions using a random-effects model.
Results: Pooled prevalence of each neurological manifestations are, smell disturbances (35.8%; 95% CI 21.4-50.2), taste disturbances (38.5%; 95%CI 24.0-53.0), myalgia (19.3%; 95% CI 15.1-23.6), headache (14.7%; 95% CI 10.4-18.9), dizziness (6.1%; 95% CI 3.1-9.2), and syncope (1.8%; 95% CI 0.9-4.6). Pooled prevalence of acute cerebrovascular disease was (2.3%; 95%CI 1.0-3.6), of which majority were ischaemic stroke (2.1%; 95% CI 0.9-3.3), followed by haemorrhagic stroke (0.4%; 95% CI 0.2-0.6), and cerebral venous thrombosis (0.3%; 95% CI 0.1-0.6).
Conclusions: Neurological symptoms are common in SARS-CoV-2 infection, and from the large number of cases reported from all over the world daily, the prevalence of neurological features might increase again. Identifying some neurological manifestations like smell and taste disturbances can be used to screen patients with COVID-19 so that early identification and isolation is possible.
Keywords: Acute cerebrovascular disease; COVID-19 neurological manifestations; Guillain-Barr? syndrome; Meningoencephalitis; SARS-CoV-2 infection; Smell and taste disturbances.
. 2020 Oct 21.
doi: 10.1007/s10072-020-04801-y. Online ahead of print.
Neurological manifestations of COVID-19: a systematic review and meta-analysis of proportions
T T Favas[SUP] 1 [/SUP], Priya Dev[SUP] 1 [/SUP], Rameshwar Nath Chaurasia[SUP] 1 [/SUP], Kamlesh Chakravarty[SUP] 2 [/SUP], Rahul Mishra[SUP] 3 [/SUP], Deepika Joshi[SUP] 1 [/SUP], Vijay Nath Mishra[SUP] 1 [/SUP], Anand Kumar[SUP] 1 [/SUP], Varun Kumar Singh[SUP] 1 [/SUP], Manoj Pandey[SUP] 4 [/SUP], Abhishek Pathak[SUP] 5 [/SUP]
Affiliations
- PMID: 33089477
- DOI: 10.1007/s10072-020-04801-y
Abstract
Background: Coronaviruses mainly affect the respiratory system; however, there are reports of SARS-CoV and MERS-CoV causing neurological manifestations. We aimed at discussing the various neurological manifestations of SARS-CoV-2 infection and to estimate the prevalence of each of them.
Methods: We searched the following electronic databases; PubMed, MEDLINE, Scopus, EMBASE, Google Scholar, EBSCO, Web of Science, Cochrane Library, WHO database, and ClinicalTrials.gov . Relevant MeSH terms for COVID-19 and neurological manifestations were used. Randomized controlled trials, non-randomized controlled trials, case-control studies, cohort studies, cross-sectional studies, case series, and case reports were included in the study. To estimate the overall proportion of each neurological manifestations, the study employed meta-analysis of proportions using a random-effects model.
Results: Pooled prevalence of each neurological manifestations are, smell disturbances (35.8%; 95% CI 21.4-50.2), taste disturbances (38.5%; 95%CI 24.0-53.0), myalgia (19.3%; 95% CI 15.1-23.6), headache (14.7%; 95% CI 10.4-18.9), dizziness (6.1%; 95% CI 3.1-9.2), and syncope (1.8%; 95% CI 0.9-4.6). Pooled prevalence of acute cerebrovascular disease was (2.3%; 95%CI 1.0-3.6), of which majority were ischaemic stroke (2.1%; 95% CI 0.9-3.3), followed by haemorrhagic stroke (0.4%; 95% CI 0.2-0.6), and cerebral venous thrombosis (0.3%; 95% CI 0.1-0.6).
Conclusions: Neurological symptoms are common in SARS-CoV-2 infection, and from the large number of cases reported from all over the world daily, the prevalence of neurological features might increase again. Identifying some neurological manifestations like smell and taste disturbances can be used to screen patients with COVID-19 so that early identification and isolation is possible.
Keywords: Acute cerebrovascular disease; COVID-19 neurological manifestations; Guillain-Barr? syndrome; Meningoencephalitis; SARS-CoV-2 infection; Smell and taste disturbances.